Psychiatric disorders are associated with shortened life expectancy (ie, shortened by as much as 10 years).1 There is a concern that psychiatric comorbidity might increase Coronavirus Disease 2019 (COVID-19)–related mortality, as suggested by prior preliminary studies of cardiac and infectious disease outcomes.2,3 A large population study in Demark suggested that an a priori diagnosis of depression was associated with a higher 30-day mortality for those hospitalized for an infection.3 Here, we evaluate the association between having any prior psychiatric diagnosis and COVID-19–related mortality of hospitalized patients with COVID-19.
Sign in to take quiz and track your certificates
JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 Credit(s)™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC
CME Disclosure Statement: Unless noted, all individuals in control of content reported no relevant financial relationships. If applicable, all relevant financial relationships have been mitigated.
Accepted for Publication: August 27, 2020.
Published: September 30, 2020. doi:10.1001/jamanetworkopen.2020.23282
Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2020 Li L et al. JAMA Network Open.
Corresponding Author: Luming Li, MD, Yale University School of Medicine, Department of Psychiatry, 184 Liberty St, New Haven, CT 06511 (email@example.com).
Author Contributions: Dr L. Li and Mr F. Li had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: L. Li, Fortunati, Krystal.
Acquisition, analysis, or interpretation of data: L. Li, F. Li.
Drafting of the manuscript: L. Li, F. Li.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: F. Li, Krystal.
Obtained funding: Krystal.
Administrative, technical, or material support: L. Li, Fortunati.
Conflict of Interest Disclosures: Dr L. Li reported grants from a Health and Aging Policy Fellowship during the conduct of the study. Dr Krystal reported receiving royalties from Janssen Pharmaceuticals, stock from Biohaven Pharmaceuticals, stock options from Blackthorn Pharmaceuticals, stock from Spring Health, stock options from Terran Biosciences, personal fees and provision of drugs for research from Novartis, provision of drugs for research from AstraZeneca, personal fees from Sunovion, Takeda, Cerevel, Biogen, EpiVario, Heptares, Otsuka, Taisho, BioXcel, and Psychogenics, stock from Sage, and personal fees from Cadent Pharmaceuticals outside the submitted work and is the editor of Biological Psychiatry and a member of the Society of Biological Psychiatry. No other disclosures were reported.
Additional Contributions: The authors would like to acknowledge Mr Todd Barnes of Yale New Haven Hospital for help reviewing the results of the study. No compensation was received for his role.
Credit Designation Statement: The American Medical Association designates this Journal-based CME activity activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to:
It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting MOC credit.
You currently have no searches saved.
You currently have no courses saved.